

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A method for ~~prevention or~~ reduction of scar ~~tissue and/or~~ adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment.
2. (Original) The method of claim 1, wherein said pro-inflammatory cytokine is selected from the group consisting of TNF, IL-1, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, GM-CSF, M-CSF, MCP-1, MIP-1, RANTES, ENA-78, OSM, FGF, PDGF, and VEGF.
3. (Original) The method of claim 1, wherein said pro-inflammatory cytokine is selected from the group consisting of TNF and IL-1.
4. (Original) The method of claim 1, for treatment of post-traumatic tissue injury.
5. (Original) The method of claim 4, wherein said post-traumatic tissue injury is caused by surgery.

6. (Original) The method of claim 1, for treatment of a thermic injury.
7. (Original) The method of claim 1, for treatment of a pathological condition with scar formation.
8. (Original) The method of claim 7, wherein said pathological condition with scar formation is caused by a vascular disease selected from the group consisting of bleeding and infarct.
9. (Original) The method of claim 7, wherein said pathological condition with scar formation is caused by a toxic influence.
10. (Original) The method of claim 7, wherein said pathological condition with scar formation is caused by cystic fibrosis.
11. - 22. (Canceled).
23. (Original) The method of claim 1, wherein said substance is lactoferrin or a peptide derived from lactoferrin.
24. (Original) The method of claim 1, wherein said substance is locally administered.

25. (Original) The method of claim 1, wherein said substance is systemically administered.